The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
May 16th 2024
Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.
Dr. Rugo on the Phase III SOPHIA Trial in HER2+ Breast Cancer
June 4th 2019Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the phase III SOPHIA trial of margetuximab plus chemotherapy versus trastuzumab (Herceptin) plus capecitabine in patients with HER2-positive metastatic breast cancer after prior anti–HER2-targeted therapies.
Dr. Mortimer on Brain Metastases in HER2+ Breast Cancer
May 24th 2019Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology and Therapeutics Research, director, Women’s Cancer Programs, and breast cancer oncologist, City of Hope, discusses brain metastases in women with HER2-positive breast cancer.
[Fam-] Trastuzumab Deruxtecan Elicits Responses in Advanced HER2+ Breast Cancer
May 8th 2019The antibody-drug conjugate [fam-] trastuzumab deruxtecan (DS-8201) demonstrated encouraging responses in patients with unresectable and/or metastatic HER2-positive breast cancer that has been previously treated with ado-trastuzumab emtansine, according to topline findings from the phase II DESTINY-BreastO1 study.
FDA Approves Adjuvant T-DM1 in HER2+ Early Breast Cancer
May 4th 2019The FDA has approved ado-trastuzumab emtansine (T-DM1; Kadcyla) for use as an adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant trastuzumab and chemotherapy.
Dr. Mortimer on Adjuvant Therapy in Early-Stage HER2+ Breast Cancer
May 3rd 2019Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology & Therapeutics Research, director, Women’s Cancer Programs, City of Hope, discusses adjuvant therapy in early-stage HER2-positive breast cancer.
[Fam]-Trastuzumab Deruxtecan Accelerates Through HER2+ Breast Cancer Pipeline
March 29th 2019An accelerated filing of a biologics license application is planned for [fam-] trastuzumab deruxtecan (DS-8201) as a treatment for patients with HER2-positive metastatic breast cancer previously treated with ado-trastuzumab emtansine.
Dr. Hurvitz on Toxicity Associated With Neratinib in HER2+ Breast Cancer
March 26th 2019Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses toxicity associated with neratinib in the treatment of patients with HER2-positive breast cancer.
Dr. Pegram on Promising Novel Agents in HER2+ Metastatic Breast Cancer
March 22nd 2019Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses promising novel agents in the treatment of patients with HER2-positive metastatic breast cancer.
Dr. Hurvitz on Standards of Care in HER2+ Breast Cancer
March 14th 2019Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the first- and second-line standards of care in HER2-positive breast cancer.
Dr. Chien on Tucatinib in HER2+ Breast Cancer
March 12th 2019A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of tucatinib (ONT-380) in the treatment of patients with HER2-positive breast cancer.
Dr. Hurvitz on FDA Approval of Subcutaneous Trastuzumab Formulation in HER2+ Breast Cancer
March 9th 2019Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the recent FDA approval of subcutaneous use of trastuzumab (Herceptin) and hyaluronidase-oysk injection (Herceptin Hylecta) in the HER2-positive breast cancer space.
Dr. Hamilton on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBC
March 8th 2019Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the FDA approval of atezolizumab and nab-paclitaxel as a frontline therapy for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.
FDA Approves Subcutaneous Trastuzumab Formulation for HER2+ Breast Cancer
February 28th 2019The FDA has approved subcutaneous use of trastuzumab and hyaluronidase-oysk injection in combination with chemotherapy for the treatment of select patients with HER2-positive early breast cancer, in combination with paclitaxel in patients with metastatic HER2-positive breast cancer as a frontline treatment, and alone for patients with metastatic disease who have received at least 1 prior chemotherapy regimen